

JAMA | Original Investigation

Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation

A Randomized Clinical Trial

David Jiménez, MD, PhD; Alvar Agustí, MD, PhD; Eva Taberner, MD; Luis Jara-Palomares, MD, PhD; Ascensión Hernando, MD, PhD; Pedro Ruiz-Artacho, MD, PhD; Gregorio Pérez-Peñate, MD, PhD; Agustina Rivas-Guerrero, MD; María Jesús Rodríguez-Nieto, MD, PhD; Aitor Ballaz, MD; Ramón Agüero, MD; Sonia Jiménez, MD; Myriam Calle-Rubio, MD, PhD; Raquel López-Reyes, MD; Pedro Marcos-Rodríguez, MD; Deisy Barrios, MD, PhD; Carmen Rodríguez, MD; Alfonso Muriel, PhD; Laurent Bertoletti, MD, PhD; Francis Couturaud, MD, PhD; Menno Huisman, MD, PhD; José Luis Lobo, MD; Roger D. Yusen, MD; Behnood Bikdeli, MD, MS; Manuel Monreal, MD, PhD; Remedios Otero, MD, PhD; for the SLICE Trial Group

IMPORTANCE Active search for pulmonary embolism (PE) may improve outcomes in patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD).

OBJECTIVE To compare usual care plus an active strategy for diagnosing PE with usual care alone in patients hospitalized for COPD exacerbation.

DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial conducted across 18 hospitals in Spain. A total of 746 patients were randomized from September 2014 to July 2020 (final follow-up was November 2020).

INTERVENTIONS Usual care plus an active strategy for diagnosing PE (D-dimer testing and, if positive, computed tomography pulmonary angiogram) (n = 370) vs usual care (n = 367).

MAIN OUTCOMES AND MEASURES The primary outcome was a composite of nonfatal symptomatic venous thromboembolism (VTE), readmission for COPD, or death within 90 days after randomization. There were 4 secondary outcomes, including nonfatal new or recurrent VTE, readmission for COPD, and death from any cause within 90 days. Adverse events were also collected.

RESULTS Among the 746 patients who were randomized, 737 (98.8%) completed the trial (mean age, 70 years; 195 [26%] women). The primary outcome occurred in 110 patients (29.7%) in the intervention group and 107 patients (29.2%) in the control group (absolute risk difference, 0.5% [95% CI, -6.2% to 7.3%]; relative risk, 1.02 [95% CI, 0.82-1.28]; $P = .86$). Nonfatal new or recurrent VTE was not significantly different in the 2 groups (0.5% vs 2.5%; risk difference, -2.0% [95% CI, -4.3% to 0.1%]). By day 90, a total of 94 patients (25.4%) in the intervention group and 84 (22.9%) in the control group had been readmitted for exacerbation of COPD (risk difference, 2.5% [95% CI, -3.9% to 8.9%]). Death from any cause occurred in 23 patients (6.2%) in the intervention group and 29 (7.9%) in the control group (risk difference, -1.7% [95% CI, -5.7% to 2.3%]). Major bleeding occurred in 3 patients (0.8%) in the intervention group and 3 patients (0.8%) in the control group (risk difference, 0% [95% CI, -1.9% to 1.8%]; $P = .99$).

CONCLUSIONS AND RELEVANCE Among patients hospitalized for an exacerbation of COPD, the addition of an active strategy for the diagnosis of PE to usual care, compared with usual care alone, did not significantly improve a composite health outcome. The study may not have had adequate power to assess individual components of the composite outcome.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: [NCT02238639](https://clinicaltrials.gov/ct2/show/study/NCT02238639)

JAMA. 2021;326(13):1277-1285. doi:10.1001/jama.2021.14846

[+ Supplemental content](#)

[+ CME Quiz at \[jamacmelookup.com\]\(https://jamacmelookup.com\) and CME Questions page 1323](#)

Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: The SLICE Trial Group members appear in Supplement 4.

Corresponding Author: David Jiménez, MD, PhD, Respiratory Department and Medicine Department, Ramón y Cajal Hospital, IRYCIS and Alcalá University, CIBER Enfermedades Respiratorias (CIBERES), Colmenar Rd, Km. 9,100, 28034 Madrid, Spain (djimenez.hrc@gmail.com).

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide and is associated with a huge economic burden for the health care system.^{1,2} Patients may have exacerbations of COPD, defined as acute worsening of respiratory symptoms that results in additional therapy,^{3,4} drives disease progression, and is associated with mortality.⁵ Common triggers of exacerbations include infections, air pollution, and noninfectious factors,⁶ although other clinical conditions may mimic the symptoms of exacerbation of COPD.⁷

Pulmonary embolism (PE) is reported to be prevalent in patients with exacerbation of COPD.⁸⁻¹¹ Because the diagnosis of PE based on clinical suspicion is not sufficiently accurate and computed tomography pulmonary angiogram (CTPA) is readily available at emergency departments, its use has significantly increased over the past 5 years in the US.¹² CTPA is a time-consuming and burdensome investigation associated with radiation exposure, contrast reactions, and high cost. In addition, the need for an active detection strategy for PE needs to be balanced against the risk of exposing additional patients to anticoagulation,¹³ because the diagnosis may not always have clinical significance (ie, subsegmental PE).¹⁴ Although observational studies and meta-analyses have assessed the prevalence of PE among patients who have exacerbations of COPD, to our knowledge, no clinical trials have evaluated whether an active search for PE might improve clinical outcomes.

The objective of the Significance of Pulmonary Embolism in COPD Exacerbations (SLICE) trial was to compare health outcomes in patients with exacerbations of COPD who required hospital admission and were randomized to undergo an active search for PE with the use of D-dimer test and CTPA or to receive usual care.

Methods

Trial Design and Oversight

This multicenter, open-label, randomized clinical trial was conducted from September 2014 through July 2020 in accordance with a previously published protocol,¹⁵ which is provided in [Supplement 1](#). The statistical analysis plan is provided in [Supplement 2](#). The institutional review board at each of the participating sites approved the protocol, and each patient provided written informed consent.

Trial Sites and Patient Population

The trial was conducted in 18 academic hospitals across Spain. Patients were eligible for inclusion if they had a diagnosis of COPD and were hospitalized for an exacerbation. Patients were excluded if PE was the initial clinical suspicion (no suspicion of PE was defined as a patient in whom the physician-in-charge would not have examined for PE outside the study) or if they were pregnant; had a contraindication to CTPA; had a diagnosis of pneumonia, pneumothorax, or lower respiratory tract infection; or needed invasive mechanical ventilation at the time of hospital admission. Complete lists of inclusion and exclusion criteria are provided in eTables 1 and 2 in [Supplement 3](#).

Key Points

Question Does an active search for pulmonary embolism (PE) improve outcomes in patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD)?

Findings This multicenter randomized clinical trial included 746 patients who required hospitalization for exacerbation of COPD and were randomized to receive usual care plus an active strategy for diagnosing PE or usual care alone. The primary outcome (a composite of nonfatal symptomatic venous thromboembolism, readmission for COPD, or death within 90 days after randomization) occurred in 29.7% of patients in the intervention group vs 29.2% in the control group, a difference that was not statistically significant.

Meaning Among patients hospitalized for an exacerbation of COPD, addition of an active diagnostic strategy for PE to usual care compared with usual care alone did not improve a composite set of health outcomes.

Randomization

Eligible patients were randomized in a 1:1 ratio to undergo usual care plus an active search for PE (intervention group) or usual care alone (control group). The permuted block (4 and 6 patients per block) randomization sequence was prepared by a statistician who was not involved in the trial. To minimize randomization bias, we performed randomization concealment with an interactive web-based response system until randomization was finished on the system through a computer. Given the nature of the intervention, clinicians and research personnel were aware of trial group assignments after randomization.

Trial Interventions

All patients received standard clinical management (usual care) for their exacerbation of COPD according to the inpatient clinician's preference and local standards ([eFigure 1](#) in [Supplement 3](#)). Typically, standard clinical management consisted of the use of supplemental oxygen, short-acting inhaled β_2 agonists and short-acting anticholinergic agents, systemic corticosteroids, antibiotics, and pharmacological thromboprophylaxis.

Patients in the intervention group underwent D-dimer testing within 12 hours after randomization. Cutoff levels for defining elevated D-dimer were established by the department of clinical chemistry at each participating site ([eTable 3](#) in [Supplement 3](#)). For patients with a negative D-dimer value, a diagnosis of PE was ruled out. For patients with a positive D-dimer value, a CTPA was performed ([eTable 4](#) in [Supplement 3](#)). CTPA results were categorized as positive for PE if an intraluminal filling defect was seen in subsegmental or more proximal branches and considered negative if no filling defect was observed. Scans were considered technically inadequate only if main or lobar pulmonary vessels were not visualized. Although it was not mandatory, the protocol suggested the use of complete lower limb compression ultrasonography to detect concomitant deep vein thrombosis (DVT) for patients with isolated subsegmental PE.

If the diagnosis of PE was confirmed, patients received anticoagulant treatment according to guideline recommendations: parenteral anticoagulation (ie, unfractionated heparin, low-molecular-weight heparin, or fondaparinux) overlapped with and followed by vitamin K antagonists, parenteral anticoagulation followed by dabigatran or edoxaban, or monotherapy with apixaban or rivaroxaban for at least 3 months.

Outcome Measures

The primary outcome was assessed within 90 days after randomization and consisted of the composite of nonfatal new or recurrent symptomatic venous thromboembolism (VTE), readmission for COPD, or death. Secondary outcomes included death from any cause within 90 days after randomization, nonfatal new or recurrent symptomatic VTE within 90 days after randomization, readmission for exacerbation of COPD within 90 days after randomization, and length of hospital stay.

Confirmation of new or recurrent symptomatic PE required symptoms of PE and a new or an extension of a previous intraluminal-filling defect in subsegmental or more proximal branches on CTPA. Confirmation of new or recurrent symptomatic DVT required symptoms of DVT and the following criteria: in the absence of previous DVT investigations at baseline, a noncompressible venous segment on ultrasonography; if there were previous DVT investigations at baseline, abnormal lower limb compression ultrasonography where compression had been normal; or, if previously noncompressible, a substantial increase (>4 mm) in diameter of the thrombus during full compression.

Evaluation of adverse events within 90 days after randomization included major bleeding, clinically relevant nonmajor bleeding, and serious adverse events. Major bleeding was defined according to the guidelines of the International Society of Thrombosis and Hemostasis as acute clinically overt bleeding associated with 1 or more among the following: a decrease in hemoglobin of 2 g/dL or more, a transfusion of 2 or more units of packed red blood cells, bleeding that occurs in at least 1 of the critical sites (intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal), bleeding that is fatal (defined as a bleeding event that the central independent committee adjudicate as the primary cause of death or contributing directly to death), and bleeding that necessitates surgical intervention.¹⁶ A bleeding event was classified as a clinically relevant nonmajor bleeding event if it was overt (ie, symptomatic or visualized by examination), did not meet the criteria for major bleeding, required medical attention, or was associated with discomfort for the patient, such as pain or impairment of activities of daily life. Serious adverse events were those that fulfilled 1 or more of the following criteria: fatal, immediately life-threatening, resulted in persistent or significant disability/incapacity, required or prolonged in-patient hospitalization, was a congenital anomaly/birth defect, or any other reason representing a significant hazard comparable to the criteria mentioned above.

A central independent adjudication committee whose members were unaware of treatment randomization adjudicated all suspected events during the study period. Trial visits were scheduled at enrollment and at 7, 30, and 90 days after randomization.

Sample Size Calculation


For a prevalence of PE of 10%, the event rate for the primary outcome was calculated to be 40%.^{17,18} An estimated 355 participants were needed in each trial group to detect a 10% absolute reduction in the primary outcome (ie, from 40% to 30%) with 80% power at a 2-sided 5% significance level. The 10% reduction was based on consultation with general practitioners and pulmonologists, who considered this reduction to be clinically important. We initially aimed to enroll 900 patients to compensate for a 25% dropout rate. An interim analysis was conducted after recruitment of 50% of the study population. To preserve an overall type I error rate of .05 for the entire trial, the O'Brien-Fleming-type boundary (α of .005) was used for early trial stoppage.

Statistical Analysis

The characteristics of the patients at baseline are reported as percentages for categorical variables and as mean (SD) and median (IQR) values for continuous variables, as appropriate. All patients who underwent randomization were included in the efficacy and safety analyses according to the treatment group to which they were assigned. In addition, safety analyses were performed among the safety analysis set, which included all patients in the control group and all patients in the intervention group who underwent D-dimer testing. Missing data were not replaced, and analyses included all evaluable patients. Because only 1 patient was lost to follow-up (in the intervention group), sensitivity analyses were performed on the primary and secondary outcomes using worst-case scenario (ie, all participants lost to follow-up had the outcome). The analyses of the primary and secondary outcomes were also replicated in the per-protocol population. In addition, subgroup analyses were carried out according to age, sex, COPD severity, hospital size, and season (Supplement 2).

The primary efficacy and safety outcome data were analyzed by means of a 2-sided χ^2 test of proportions. A post hoc analysis was applied to account for a possible clustering effect at the enrolling site level. For this purpose, a mixed-effect model including site of enrollment as a random effect was performed. In another post hoc analysis, we examined whether an age-adjusted D-dimer cutoff, defined as age (in years) multiplied by 10 in patients 50 years or older, was associated with an increased diagnostic yield of D-dimer in this population. Because of the potential for type I error due to multiple comparisons, findings for analyses of secondary end points should be interpreted as exploratory. Kaplan-Meier survival curves until 90 days after randomization were compared with a log-rank test. The significance threshold was 2-sided at .05. All statistical analyses were performed with the use of the SPSS/PC software package, version 26 (SPSS), and Stata software, version 16.1 (StataCorp).

Figure 1. Flow of Patients in a Study of the Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes



Results

After 450 patients underwent randomization, a predefined interim analysis showed a 3% dropout rate that was lower than anticipated, and the data and safety monitoring board recommended to decrease the sample size to 746 (to account for a 5% dropout rate) and to continue the trial to the end.

Patients

From September 2014 through July 2020, a total of 1003 patients were screened for inclusion in the trial, of whom 746 (74.4%) underwent randomization (Figure 1). Four patients were receiving anticoagulants at the time of randomization, 3 patients withdrew consent to use their data, and 2 underwent randomization in error, which left 370 patients in the intervention group and 367 in the usual care group. Overall, the mean (SD) age was 70.4 (9.9) years, and 195 (26%) patients were women. The demographic and clinical characteristics of the patients at baseline did not differ between the 2 trial groups (Table 1). All patients in the control group and all patients in the intervention group without PE during the initial diagnostic period received at least 1 prophylactic dose of low-molecular-weight heparin.

Trial Interventions

Overall, 369 of 370 patients (99.7%) randomized to the intervention group received a D-dimer test within 12 hours after randomization, and the median (IQR) D-dimer value was 560 (353-1055) ng/mL. Among these 369 patients, 183 (49.6%) had negative D-dimer values and a diagnosis of PE was ruled out. A CTPA was performed in 11 patients (6.0%) with a negative D-dimer value and a segmental PE was diagnosed in 1 patient

(0.5% [95% CI, 0.0%-3.0%]). Although none of these patients had a clinical suspicion of PE at the time of randomization, investigators sped up the trial procedures and ordered a CTPA before being aware of the results of the D-dimer test. Among the 186 patients with a positive D-dimer value, a CTPA was performed in 181 (97.3%). CTPA findings showed PE in 16 patients (8.8% [95% CI, 5.1%-14.0%]): central in 7 patients (43.8%), segmental in 7 patients (43.8%), and multiple subsegmental in 2 patients (12.4%). No patients underwent a compression ultrasonography. Therefore, the prevalence of PE among the 192 patients who underwent a CTPA was 8.9% and the overall rate of PE found in the intervention group during the initial diagnostic period was 17 of 370 patients (4.6% [95% CI, 2.7%-7.3%]). Eleven (65% [95% CI, 38%-86%]) of these patients received low-molecular-weight heparin overlapped with and followed by vitamin K antagonists, 4 (24% [95% CI, 6.8%-50%]) received apixaban, and 2 (12% [95% CI, 1.5%-36%]) received rivaroxaban. None of these patients required fibrinolytic therapy, surgical or percutaneous thrombectomy, or an inferior vena cava filter. CTPA findings that supported an alternative diagnosis were detected in 133 patients (76.0%) (eTable 5 in Supplement 3).

As per protocol, none of the 367 patients in the control group received workups for diagnosis of PE unless a suspicion of this diagnosis arose after randomization. Five patients in the control group underwent a CTPA because of suspicion for PE during the index admission, and PE was confirmed in 3 patients (all nonfatal).

Primary Outcome

At 90 days, 110 patients (29.7%) in the intervention group and 107 (29.2%) in the usual care group experienced the primary composite outcome (absolute risk difference, 0.5% [95% CI,

Table 1. Baseline Characteristics of Patients in a Study of the Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation

Characteristic	No. (%)	
	Intervention group (n = 370)	Control group (n = 367)
Age, mean (SD), y	70.2 (9.9)	70.6 (9.9)
Sex		
Men	284 (76.8)	258 (69.7)
Women	86 (23.2)	109 (30.3)
Current smoker	119 (32.2)	111 (30.2)
Pack-years of smoking, mean (SD)	58.8 (27.1) [n = 119]	57.8 (26.6) [n = 111]
COPD exacerbations in the past 12 mo, mean (SD)	1.3 (1.8)	1.4 (1.6)
FEV ₁ after administration of albuterol, mean (SD), % of the predicted normal value	46.2 (18.1)	45.8 (16.3)
COPD		
Very severe: <30% of the predicted normal value	56 (15.1)	58 (15.8)
Severe: 30% to <50% of the predicted normal value	170 (45.9)	162 (44.1)
Moderate: 50% to <80% of the predicted normal value	113 (30.5)	119 (32.4)
Mild: ≥80% of the predicted normal value	29 (7.8)	28 (7.6)
Previous treatment		
Long-acting β-agonist	329 (88.9)	337 (91.8)
Long-acting anticholinergic	313 (84.6)	319 (86.9)
Inhaled corticosteroid	267 (72.2)	277 (75.5)
Risk factors for VTE		
Immobilization ^a	67 (18.1)	66 (18.0)
Sleep apnea	56 (15.1)	55 (15.0)
Congestive heart failure	48 (13.0)	50 (13.6)
Cancer ^b	12 (3.2)	14 (3.8)
History of VTE	10 (2.7)	15 (4.1)
Surgery ^c	1 (0.3)	2 (0.5)
Clinical symptoms and signs at presentation		
Dyspnea	368 (99.5)	367 (100)
Heart rate >100/min	129 (34.9)	135 (36.8)
Increased sputum volume	129 (34.9)	127 (34.6)
Purulent sputum	24 (6.5)	24 (6.5)
Systolic blood pressure <100 mm Hg	12 (3.2)	8 (2.2)
Wells score		
Low clinical probability	163 (44)	162 (44)
Intermediate clinical probability	206 (56)	204 (56)
High clinical probability	1 (0.3)	1 (0.3)
pH	(n = 315)	(n = 326)
<7.35	45 (14)	63 (19)
7.35-7.45	222 (70)	226 (69)
>7.45	49 (16)	37 (11)

(continued)

Table 1. Baseline Characteristics of Patients in a Study of the Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation (continued)

Characteristic	No. (%)	
	Intervention group (n = 370)	Control group (n = 367)
Pao ₂ , mm Hg		
≥60	161 (51)	148 (45)
50-59	92 (29)	106 (33)
<50	62 (20)	72 (22)
Paco ₂ , mm Hg		
≤45	167 (53)	161 (49)
46-55	81 (26)	74 (23)
>55	67 (21)	91 (28)
SpO ₂ <90%	145 (40) [n = 367]	134 (37) [n = 365]
Admission blood tests		
Creatinine, mean (SD), mg/dL	0.9 (0.3)	0.9 (0.3)
Creatinine >1.5 mg/dL	6 (1.6)	12 (3.3)
Hemoglobin, mean (SD), g/dL	14.3 (2.1)	14.1 (1.8)
Leukocytes, mean (SD), ×10 ⁹ /L	10.9 (7.1)	10.9 (4.6)
Treatment for exacerbation		
Short-acting inhaled β ₂ -agonists	364 (98)	366 (100)
Short-acting inhaled anticholinergics	370 (100)	365 (99)
Systemic corticosteroids	301 (81)	305 (83)
Antibiotics	249 (67)	270 (74)
Pharmacological thromboprophylaxis (LMWH)	370 (100)	367 (100)

Abbreviations: COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in the first second; LMWH, low-molecular-weight heparin; VTE, venous thromboembolism.

^a In the previous month.

^b Active or receiving treatment in the past year.

^c Defined as nonsurgical patients who had been immobilized (ie, total bed rest with bathroom privileges) for ≥4 days in the month prior to exacerbation of COPD.

–6.2%–7.3%]; relative risk, 1.02 [95% CI, 0.82 to 1.28]; *P* = .86) (Table 2). The hazard ratio for the composite outcome within 90 days after randomization in the intervention group, compared with the usual care group, was 1.0 (95% CI, 0.8–1.3); *P* = .82) (Figure 2).

Secondary Outcomes


During the follow-up period, 15 patients (4.1%) in the intervention group and 18 patients (4.9%) in the control group underwent a CTPA because of suspicion for PE. Nonfatal new or recurrent symptomatic venous thromboembolism occurred in 2 patients (0.5%) in the intervention group and in 9 patients (2.5%) in the control group (risk difference, –2.0% [95% CI, –4.3%–0.1%]; relative risk, 0.22 [95% CI, 0.05–1.01]) (Table 2; eFigure 2 and eFigure 3 in Supplement 3). All thrombotic events were PEs (2 lobar in the intervention group and 1 central, 4 lobar, and 4 segmental in the control group). There was no evidence of a significant between-group difference in readmissions for an exacerbation of COPD: 94 of 370 patients (25.4%)

Table 2. Outcomes in a Study of the Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation

Outcome	No. (%)		Absolute difference (95% CI), %	Relative risk (95% CI)	P value
	Intervention (n = 370)	Control (n = 367)			
Primary outcome					
Composite of nonfatal new or recurrent symptomatic VTE, readmission for exacerbation of COPD, or death from any cause	110 (29.7)	107 (29.2)	0.5 (−6.2 to 7.3)	1.02 (0.82 to 1.28)	.86
Secondary outcomes					
Nonfatal new or recurrent symptomatic VTE	2 (0.5)	9 (2.5)	−2.0 (−4.3 to 0.1)	0.22 (0.05 to 1.01)	
Nonfatal new or recurrent DVT	0	0			
Nonfatal new or recurrent PE	2	9			
Readmission for exacerbation of COPD	94 (25.4)	84 (22.9)	2.5 (−3.9 to 8.9)	1.11 (0.86 to 1.43)	
Death from any cause	23 (6.2)	29 (7.9)	−1.7 (−5.7 to 2.3)	0.79 (0.46 to 1.43)	
Time to discharge, median (IQR), d	6.0 (4.0-9.0)	6.0 (4.0-8.0)		0.68 (−0.29 to 1.66) ^a	
Adverse events					
Major bleeding	3 (0.8)	3 (0.8)	0 (−1.9 to 1.8)	0.99 (0.20 to 4.88)	.99
Clinically relevant nonmajor bleeding	1 (0.3)	1 (0.3)	0 (−1.5 to 1.5)	0.99 (0.06 to 15.80)	
Serious adverse events	18 (4.9)	18 (4.9)	0 (−3.5 to 3.4)	0.99 (0.53 to 1.88)	

Abbreviations: COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism.
^a Difference (intervention minus control) is shown for mean values.

Figure 2. Composite Outcome in a Study of the Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes



The median (IQR) observation time was 90 (70-90) days for the intervention group and 90 (76-90) days for the control group.

in the intervention group and 84 of 367 patients (22.9%) in the usual care group (risk difference, 2.5% [95% CI, −3.9%-8.9%]; relative risk, 1.11 [95% CI, 0.86-1.43]) (Table 2; eFigure 2 and eFigure 3 in Supplement 3). At 90 days, 23 patients (6.2%) in the intervention group and 29 (7.9%) in the control group died (risk difference, −1.7% [95% CI, −5.7%-2.3%]; relative risk, 0.79 [95% CI, 0.46-1.33]) (Table 2; eFigure 2 and eFigure 3 in Supplement 3). COPD was the most common cause of death in the 2 groups (eTable 6 in Supplement 3). The median (IQR) duration of hospitalization among patients was 6 (4-9) days in the intervention group and 6 (4-8) days in the control group.

Secondary and Subgroup Analyses

The results, with respect to the intervention effect, were consistent in safety and sensitivity analyses and in analyses of the per-protocol cohort (eTable 7 in Supplement 3). Further, findings were similar across the prespecified subgroups (eFigure 4 in Supplement 3). The estimate of the intervention effect for the primary outcome did not change when a post hoc mixed-effect model, including site of enrollment as random effect, was performed (odds ratio, 1.02 [95% CI, 0.74-1.40]). In a post hoc sensitivity analysis that used an age-adjusted D-dimer cutoff, 51 of 181 patients were reclassified into the

group with negative D-dimer values. Therefore, the use of the age-adjusted cutoff resulted in a 13.8% absolute increase in the percentage of negative D-dimer test results. One of the patients with a negative age-adjusted D-dimer result had a segmental PE.

Adverse Events

Major bleeding occurred in 3 of 370 patients (0.8%) in the intervention group and in 3 of 367 (0.8%) in the usual care group (risk difference, 0.0% [95% CI, -1.9% to 1.8%]; relative risk, 1.0 [95% CI, 0.2-4.9]; $P = .99$). There were no fatal bleeding episodes in the intervention group and 1 in the usual care group. The sites of major bleeding in the groups are reported in eTable 8 in Supplement 3. Clinically relevant nonmajor bleeding occurred in 1 patient (0.3%) in the intervention group and in 1 patient (0.3%) in the usual care group (risk difference, 0% [95% CI, -1.5% to 1.5%]; relative risk, 1.0 [95% CI, 0.1 to 15.8]). The percentages of patients experiencing serious adverse events were not significantly different in the two groups: 4.9% in the intervention group and 4.9% in the usual care group (risk difference, 0% [95% CI, -3.5% to 3.4%]; relative risk, 1.0 [95% CI, 0.5 to 1.9]).

Discussion

This multicenter randomized trial involving patients who required hospitalization for exacerbations of COPD showed that an active strategy for the diagnosis of PE (D-dimer testing and, if positive, CTPA) did not result in a lower percentage of patients having the composite outcome of nonfatal new or recurrent VTE, readmission for COPD, or death within 90 days after randomization. The lack of effect was observed using the complete data set with a low dropout rate, and it was supported by sensitivity and subgroup analyses.

The frequency of PE in the intervention group in this trial was similar to that in a previous study in which 3.3% of patients admitted to the emergency departments of 2 academic teaching hospitals for acute exacerbation of moderate to very severe COPD had concurrent PE¹⁰ and lower than in a previous study in which the prevalence of PE detected via CT in 197 patients with COPD who were admitted to the hospital for severe exacerbation of unknown origin was 22%.⁹ Study design, setting, and patient selection might account for the difference in PE prevalence between the study by Tillie-Leblond et al⁹ and the current trial. The former was a single-center prospective study that was conducted in a large referral inpatient respiratory department. Therefore, it might not be representative of the patients treated by emergency physicians in general hospitals. Moreover, patients with COPD and an initial suspicion of PE were not excluded from the study, which potentially led to the selective enrollment of patients with a higher probability of PE and a high cancer rate of 29%. In addition, a 2021 cross-sectional study showed a very similar 4.3% prevalence of PE among patients who required hospitalization for exacerbation of COPD in whom PE was not suspected.¹⁹

Because one of the exclusion criteria in this trial was an initial clinical suspicion of PE, enrolled patients did not have

high clinical probability of PE and pretest clinical probability assessment was deemed unnecessary in the diagnostic pathway. Accordingly, and because of its very high negative predictive value among patients with a low or intermediate clinical pretest probability,²⁰ the study chose to include D-dimer testing as the initial step. In the intervention group, half of the patients had PE ruled out by a D-dimer level lower than the predetermined cutoff value, with a low likelihood of subsequent symptomatic PE. Therefore, considering PE to be ruled out in patients with exacerbations of COPD who have a negative D-dimer test result seems appropriate. Although previous studies have shown that a D-dimer cutoff adjusted to patients' age might increase the clinical usefulness without compromising safety,^{21,22} the trial used a fixed D-dimer cutoff. A post hoc sensitivity analysis showed that the use of an age-adjusted D-dimer cutoff resulted in a 14% absolute increase in the percentage of negative D-dimer test results in the intervention group with a very low 90-day VTE risk.

Episodes of new or recurrent VTE and death (which were components of the primary outcome) were numerically lower in the intervention group, and the results could not rule out an absolute decrease of 4.3% in new or recurrent VTE and 5.7% in new or recurrent mortality. All recurrences that were diagnosed in the follow-up period were PEs. This result is not unexpected, because patients with COPD and acute symptomatic VTE present more frequently with PE than with DVT, and those with a history of PE are at increased risk for recurrent PE (vs DVT).^{23,24}

Although the trial showed that an active strategy for the diagnosis of PE was not beneficial, some clinicians use CTPA to detect potential alternative diagnoses. Similar to previous studies, CTPA identified an alternative diagnosis in a large proportion of patients in the study.²⁵ However, the alternative diagnosis had therapeutic consequences in only 23% of the patients, and specific treatments did not result in improvement in patient outcomes.

The strength of the study is that it was set in routine practice in a large, representative, mixed sample of hospitals to enhance generalizability. It was large enough study to provide estimates with reasonable precision in the overall study population. Although the patients and clinicians could not be blinded, the trial used central, blind adjudication of outcomes. Very few patients were lost to follow-up, allowing the intention-to-treat principle to be met.

Limitations

This study has several limitations. First, the observed frequency of PE in the intervention group was lower than expected, and the results do not rule out the possibility of a clinically important treatment effect. However, the trial was designed on the premise that a sizable protective effect would be needed to justify the costs and risks of a CTPA. In addition, the trial was not powered to show a possible favorable difference in new or recurrent VTE or all-cause mortality, which would have required a very large sample size. Second, because the study had an open-label design, there is potential for diagnostic suspicion bias, in which clinicians more often suspect a new (or recurrent) VTE event if the patient has not

undergone a CTPA.²⁶ Nonetheless, the absolute number of patients with suspected recurrence was low and not significantly different in the 2 groups. Third, the findings in the study population might not apply to other patients with COPD. However, the inclusion and exclusion criteria were intended to be consistent with the pattern of patients admitted to the hospital with exacerbations of COPD. Fourth, the inclusion of readmission for COPD in the composite outcome might be questioned because it is less clinically important than VTE or death. Because some of these readmissions might be secondary to PE, and ordering a CTPA for every readmitted patient was deemed infeasible, it was felt to be justified to including these events

in the composite to ascertain the effect of the intervention on diagnosed and potentially undiagnosed PE events.

Conclusions

Among patients hospitalized for an exacerbation of COPD, the addition of an active strategy for the diagnosis of PE to usual care, compared with usual care alone, did not significantly improve a composite health outcome. The study may not have had adequate power to assess individual components of the composite outcome.

ARTICLE INFORMATION

Accepted for Publication: August 16, 2021.

Author Affiliations: Respiratory Department, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, Madrid, Spain (D. Jiménez, Barrios, Rodríguez); Medicine Department, Universidad de Alcalá, Madrid, Spain (D. Jiménez); CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain (D. Jiménez, Ruiz-Artacho, Rodríguez-Nieto, Monreal, Otero); Respiratory Institute, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Spain (Agusti); Respiratory Department, Hospital Universitario Cruces, Biocruces-Bizkaia, Barakaldo, Spain (Tabernero); Respiratory Department, Virgen del Rocío Hospital and Instituto de Biomedicina, Sevilla (Jara-Palomares, Otero); Respiratory Department, Hospital Doce de Octubre, Madrid, Spain (Hernando); Department of Internal Medicine, Clínica Universidad de Navarra, Madrid; Interdisciplinar Teragnosis and Radiomics Research Group (INTRA-Madrid), Universidad de Navarra, Madrid, Spain (Ruiz-Artacho); Respiratory Department and Pulmonary Vascular Unit, HUGC Dr. Negrín, Las Palmas GC, Spain (Pérez-Peñate); Respiratory Department, Hospital Araba, Vitoria, Spain (Rivas-Guerrero, Lobo); Respiratory Department, Fundación Jiménez Díaz, Madrid, Spain (Rodríguez-Nieto); Respiratory Department, Hospital Galdakao-Usansolo, Bilbao, Spain (Ballaz); Respiratory Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain (Agüero); Emergency Department, Hospital Clinic, IDIBAPS, Barcelona, Spain (S. Jiménez); Respiratory Department, Hospital Clínico San Carlos, Madrid; Medicine Department, Universidad Complutense, Madrid, Spain (Calle-Rubio); Respiratory Department, Hospital La Fe, Valencia, Spain (López-Reyes); Respiratory Department, Complejo Hospitalario Universitario de A Coruña (CHUAC), INIBIC, Universidade da Coruña, A Coruña, Spain (Marcos-Rodríguez); Biostatistics Department, Ramón y Cajal Hospital and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, CIBERESP, Madrid, Spain (Muriel); CHU de St-Etienne, Service de Médecine Vasculaire et Thérapeutique; INSERM, UMR1059, Université Jean-Monnet; INSERM, CIC-1408, CHU de Saint-Etienne; INNOVTE, CHU de Saint-Etienne; all in F-42055, Saint-Etienne, France (Bertoletti); Department of Internal Medicine and Chest Diseases, EA3878 (G.E.T.B.O.), CIC INSERM 0502, University Hospital of Brest, European University of Occidental Brittany, Brest, France (Couturaud); Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands (Huisman); Divisions of

Pulmonary and Critical Care Medicine and General Medical Sciences, Washington University School of Medicine in St Louis, St Louis, Missouri (Yusen); Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Bikdeli); Center for Outcomes Research and Evaluation (CORE), Yale University School of Medicine, New Haven, Connecticut (Bikdeli); Cardiovascular Research Foundation, New York, New York (Bikdeli); Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona; Universidad Católica de Murcia, Murcia, Spain (Monreal).

Author Contributions: Dr D. Jiménez had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: D. Jimenez, Calle Rubio, Rodriguez, Bertoletti, Yusen, Monreal, Otero.

Acquisition, analysis, or interpretation of data:

D. Jimenez, Agusti, Tabernero, Jara-Palomares, Hernando, Ruiz-Artacho, Perez-Peñate, Rivas-Guerrero, Rodriguez Nieto, Ballaz, Aguero, S. Jimenez, Calle Rubio, Lopez-Reyes, Marcos, Barrios, Muriel, Bertoletti, Couturaud, Huisman, Lobo, Yusen, Bikdeli, Monreal, Otero.

Drafting of the manuscript: D. Jimenez, Agusti, Marcos, Barrios, Rodriguez.

Critical revision of the manuscript for important intellectual content: D. Jimenez, Agusti, Tabernero, Jara-Palomares, Hernando, Ruiz-Artacho, Perez-Peñate, Rivas-Guerrero, Rodriguez Nieto, Ballaz, Aguero, S. Jimenez, Calle Rubio, Lopez-Reyes, Marcos, Muriel, Bertoletti, Couturaud, Huisman, Lobo, Yusen, Bikdeli, Monreal, Otero.

Statistical analysis: D. Jimenez, Marcos, Muriel, Yusen.

Obtained funding: D. Jimenez, Jara-Palomares, Barrios, Otero.

Administrative, technical, or material support:

D. Jimenez, Perez-Peñate, Lopez-Reyes, Marcos.

Supervision: D. Jimenez, Agusti, Rivas-Guerrero, Calle Rubio, Marcos, Bertoletti, Huisman, Monreal, Otero.

Conflict of Interest Disclosures: Dr D. Jimenez reported receiving personal fees from Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Leo Pharma, and Pfizer and grants from Daiichi Sankyo, Rovi, and Sanofi outside the submitted work. Dr Agusti reported receiving grants and personal fees from AstraZeneca, GlaxoSmithKline, and Menarini and personal fees from Chiesi outside the submitted work. Dr Jara-Palomares reported receiving grants from Leo Pharma and MSD and personal fees from Daiichi, Rovi, GlaxoSmithKline, and Actelion

outside the submitted work. Dr Ruiz-Artacho reported receiving personal fees from Bristol Myers Squibb, Leo Pharma, and Daiichi Sankyo and grants from ROVI outside the submitted work. Dr Calle Rubio reported receiving personal fees from Boehringer Ingelheim, AstraZeneca, Menarini, Novartis, Grifols, and GlaxoSmithKline and consulting fees from GlaxoSmithKline, Gebro Pharma, and Novartis during the conduct of the study. Dr Bertoletti reported receiving personal fees from board, symposia, and congress travel from Actelion, Aspen, Bayer, Bristol Myers Squibb/Pfizer, Leo Pharma, and MSD and travel support from Daiichi Sankyo outside the submitted work. Dr Couturaud reported receiving grants from Bristol Myers Squibb; personal fees from Bayer, AstraZeneca, and Bristol Myers Squibb; and travel support from Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, InterMune, and Actelion outside the submitted work. Dr Huisman reported receiving grants from Pfizer-Bristol Myers Squibb Alliance, Bayer Health Care, ZonMw, the Dutch Heart Foundation outside the submitted work. Dr Yusen reported receiving personal fees from Ortho Pharmaceuticals for providing expert review of venous thromboembolism cases and relationship to hormonal contraceptive therapy, Organon for providing expert review of venous thromboembolism cases and relationship to hormonal contraceptive therapy, Merck for providing expert review of venous thromboembolism cases and relationship to hormonal contraceptive therapy, Portola for providing consulting related to the oral anticoagulant betrixaban, and Janssen for providing consulting related to the oral anticoagulant rivaroxaban and grants from Cyclomedica for funding as a co-investigator of a study of an imaging agent, Technegas, outside the submitted work. Dr Bikdeli reported being a consulting expert, on behalf of the plaintiff, for litigation related to 2 specific brand models of inferior vena cava filters. Dr Monreal reported receiving educational grants from Sanofi and Rovi Pharmaceuticals for research and personal fees from Sanofi and Leo Pharma for advisory committees outside the submitted work. No other disclosures were reported.

Funding/Support: This work was supported by grants from the Instituto de Salud Carlos III (PI14/00400), Chest Foundation, Sociedad Española de Neumología y Cirugía Torácica (SEPAR), Neumosur, and Daiichi Sankyo.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or

approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: A listing of the SLICE investigators appears in [Supplement 4](#).

Data Sharing Statement: See [Supplement 5](#).

Additional Contributions: We express our gratitude to S&H Medical Science Service for their quality control data, logistic, and administrative support.

REFERENCES

1. *Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2020 Report*. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2020. Accessed January 10, 2021. https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf
2. Miravittles M, Soler-Cataluña JJ, Calle M, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017: pharmacological treatment of stable phase. *Arch Bronconeumol*. 2017;53(6):324-335. doi:10.1016/j.arbres.2017.03.018
3. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med*. 2001;163(5):1256-1276. doi:10.1164/ajrccm.163.5.2101039
4. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med*. 2013;187(4):347-365. doi:10.1164/rccm.201204-0596PP
5. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. *Lancet*. 2007;370(9589):786-796. doi:10.1016/S0140-6736(07)61382-8
6. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. *Am J Respir Crit Care Med*. 2006;173(10):1114-1121. doi:10.1164/rccm.200506-859OC
7. Beghé B, Verduri A, Roca M, Fabbri LM. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. *Eur Respir J*. 2013;41(4):993-995. doi:10.1183/09031936.00180812
8. Winter JH, Buckler PW, Bautista AP, et al. Frequency of venous thrombosis in patients with an exacerbation of chronic obstructive lung disease. *Thorax*. 1983;38(8):605-608. doi:10.1136/thx.38.8.605
9. Tillie-Leblond I, Marquette CH, Perez T, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. *Ann Intern Med*. 2006;144(6):390-396. doi:10.7326/0003-4819-144-6-200603210-00005
10. Rutschmann OT, Cornuz J, Poletti PA, et al. Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease? *Thorax*. 2007;62(2):121-125. doi:10.1136/thx.2006.065557
11. Rizkallah J, Man SFP, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. *Chest*. 2009;135(3):786-793. doi:10.1378/chest.08-1516
12. Kline JA, Garrett JS, Sarmiento EJ, Strachan CC, Courtney DM. Over-testing for suspected pulmonary embolism in American emergency departments: the continuing epidemic. *Circ Cardiovasc Qual Outcomes*. 2020;13(1):e005753. doi:10.1161/CIRCOUTCOMES.119.005753
13. Nijkeuter M, Söhne M, Tick LW, et al; Christopher Study Investigators. The natural course of hemodynamically stable pulmonary embolism: clinical outcome and risk factors in a large prospective cohort study. *Chest*. 2007;131(2):517-523. doi:10.1378/chest.05-2799
14. Anderson DR, Kahn SR, Rodger MA, et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. *JAMA*. 2007;298(23):2743-2753. doi:10.1001/jama.298.23.2743
15. Jiménez D, Agustí A, Monreal M, et al; SLICE investigators. The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. *Clin Cardiol*. 2019; 42(3):346-351. doi:10.1002/clc.23161
16. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S; Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. *J Thromb Haemost*. 2015; 13(11):2119-2126. doi:10.1111/jth.13140
17. Aleva FE, Voets LWLM, Simons SO, de Mast Q, van der Ven AJAM, Heijdra YF. Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: a systematic review and meta-analysis. *Chest*. 2017;151(3):544-554. doi:10.1016/j.chest.2016.07.034
18. Pozo-Rodríguez F, López-Campos JL, Alvarez-Martínez CJ, et al; AUDIPOC Study Group. Clinical audit of COPD patients requiring hospital admissions in Spain: AUDIPOC study. *PLoS One*. 2012;7(7):e42156. doi:10.1371/journal.pone.0042156
19. Couturaud F, Bertolletti L, Pastre J, et al; PEP Investigators. Prevalence of pulmonary embolism among patients with COPD hospitalized with acutely worsening respiratory symptoms. *JAMA*. 2021;325(1):59-68. doi:10.1001/jama.2020.23567
20. Kearon C, de Wit K, Parpia S, et al; PEGED Study Investigators. Diagnosis of pulmonary embolism with D-dimer adjusted to clinical probability. *N Engl J Med*. 2019;381(22):2125-2134. doi:10.1056/NEJMoa1909159
21. Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. *JAMA*. 2014;311(11):1117-1124. doi:10.1001/jama.2014.2135
22. Robert-Ebadi H, Robin P, Hugli O, et al. Impact of age-adjusted D-dimer cutoff to exclude pulmonary embolism: a multinational prospective real-life study (the RELAX-PE study). *Circulation*. 2021;143(18):1828-1830. doi:10.1161/CIRCULATIONAHA.120.052780
23. Bertolletti L, Quenet S, Mismetti P, et al; RIETE Investigators. Clinical presentation and outcome of venous thromboembolism in COPD. *Eur Respir J*. 2012;39(4):862-868. doi:10.1183/09031936.00058811
24. Eichinger S, Weltermann A, Minar E, et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. *Arch Intern Med*. 2004;164(1):92-96. doi:10.1001/archinte.164.1.92
25. van Es J, Douma RA, Schreuder SM, et al. Clinical impact of findings supporting an alternative diagnosis on CT pulmonary angiography in patients with suspected pulmonary embolism. *Chest*. 2013; 144(6):1893-1899. doi:10.1378/chest.13-0157
26. Beyer-Westendorf J, Büller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? *J Thromb Haemost*. 2011;9(11):2153-2158. doi:10.1111/j.1538-7836.2011.04507.x